Metsera, Inc. - Common Stock (MTSR)
52.12
+0.00 (0.00%)
NASDAQ · Last Trade: Oct 2nd, 4:32 AM EDT
Detailed Quote
Previous Close | 52.12 |
---|---|
Open | - |
Bid | 52.00 |
Ask | 52.12 |
Day's Range | N/A - N/A |
52 Week Range | 12.30 - 54.47 |
Volume | 316 |
Market Cap | - |
PE Ratio (TTM) | -4.050 |
EPS (TTM) | -12.9 |
Dividend & Yield | N/A (N/A) |
1 Month Average Volume | 3,401,829 |
Chart
News & Press Releases
These stocks could see growth take off over the next few years.
Via The Motley Fool · October 1, 2025
Metsera's MET-097i cut weight up to 14% in Phase 2b trials, with manageable side effects, as the company targets a global Phase 3 program in 2025.
Via Benzinga · September 30, 2025
The company recently announced an acquisition that will bolster its growth prospects in the GLP-1 obesity market.
Via The Motley Fool · September 30, 2025
Placebo-subtracted mean weight loss up to 14.1% after 28 weeks with no plateau
By Metsera, Inc. · Via GlobeNewswire · September 29, 2025
NEW YORK, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
By Halper Sadeh LLC · Via GlobeNewswire · September 29, 2025
BALA CYNWYD, Pa., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.
By Brodsky & Smith LLC · Via GlobeNewswire · September 29, 2025
Right now, these dividend payers are top options for folks who like to set it and forget it.
Via The Motley Fool · September 29, 2025
Pfizer is facing a patent cliff and has a high payout ratio, but it is taking steps to get back on track.
Via The Motley Fool · September 28, 2025
The company continues to improve its pipeline.
Via The Motley Fool · September 27, 2025
Pfizer is undergoing a new acquisition, exposing it to the weight loss market and additional revenue growth potential, which isn't priced in yet.
Via MarketBeat · September 26, 2025
The pharmaceutical giant is again plunging headfirst into weight-loss drug development.
Via The Motley Fool · September 26, 2025
These dividend stocks offer high yields and growth catalysts that could support payouts for decades.
Via The Motley Fool · September 26, 2025
NEW YORK, Sept. 23, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
By Halper Sadeh LLC · Via GlobeNewswire · September 23, 2025
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale Metsera, Inc. (NasdaqGS: MTSR) to Pfizer Inc. (NYSE: PFE). Under the terms of the proposed transaction, shareholders of Metsera will receive $47.50 per share in cash at closing, plus a non-transferable contingent value right entitling holders to potential additional payments of up to $22.50 per share in cash tied to three specific clinical and regulatory milestones. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
By Kahn Swick & Foti, LLC · Via Business Wire · September 23, 2025
NEW YORK, Sept. 23, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
By Halper Sadeh LLC · Via GlobeNewswire · September 23, 2025
Pfizer's plan to enter the booming obesity market took an expensive new turn.
Via The Motley Fool · September 23, 2025
BTIG said Pfizer’s $7.3 billion Metsera acquisition sharpens its clinical updates and strategic optionality.
Via Stocktwits · September 22, 2025
Stay up-to-date with the latest market trends one hour before the close of the markets on Monday. Explore the top gainers and losers during today's session in our detailed report.
Via Chartmill · September 22, 2025
Pfizer's own GLP-1 drug candidate failed earlier this year -- so it's buying someone else's.
Via The Motley Fool · September 22, 2025
Nvidia, Metsera, Oracle, Apple, Compass: Stocks Making The Biggest Moves Todaystocktwits.com
Via Stocktwits · September 22, 2025
BALA CYNWYD, Pa., Sept. 22, 2025 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.
By Brodsky & Smith LLC · Via GlobeNewswire · September 22, 2025
Via Benzinga · September 22, 2025
Looking for insights into the US markets in the middle of the day on Monday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.
Via Chartmill · September 22, 2025
Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Monday. Let's explore the market movements and identify the stocks with significant gaps.
Via Chartmill · September 22, 2025